Replimune (REPL) Assets Average (2018 - 2026)
Replimune (REPL) posted Assets Average of $333.0 million for Q1 2026, down 7.89% sequentially from $361.5 million in Q4 2025, and down 42.34% YoY from $577.5 million in Q1 2025.
Analysis
Replimune (REPL) Assets Average (2018 - 2026) Analysis & Trends
Replimune has reported Assets Average for 9 years, with the latest figure at $333.0 million in Q1 2026.
- Quarterly Assets Average fell 42.34% year-over-year to $333.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $333.0 million (down 42.34% YoY) and the FY2026 annual result came in at $441.9 million, down 14.95% from the prior year.
- Assets Average retreated to $333.0 million in Q1 2026 per REPL's latest filing, from $361.5 million in the prior quarter.
- Over five years, Assets Average peaked at $662.6 million in Q1 2023 and troughed at $333.0 million in Q1 2026.
- A 5-year average of $509.3 million and a median of $511.3 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2026: Assets Average surged 40.01% in 2023, then plunged 42.34% in 2026.
- Over 5 years, Assets Average stood at $557.3 million in 2022, then dropped by 1.73% to $547.7 million in 2023, then gained by 0.59% to $550.9 million in 2024, then sank by 34.38% to $361.5 million in 2025, then retreated by 7.89% to $333.0 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $333.0 million, $361.5 million, and $429.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Replimune | 1.45 Bn | 1.45 Bn | - | 292.42 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 292.42 Mn |
| Mar 31, 2026 | 332.99 Mn |
| Dec 31, 2025 | 361.52 Mn |
| Sep 30, 2025 | 429.48 Mn |
| Jun 30, 2025 | 510.42 Mn |
| Mar 31, 2025 | 577.48 Mn |
| Dec 31, 2024 | 550.92 Mn |
| Sep 30, 2024 | 516.58 Mn |
| Jun 30, 2024 | 511.34 Mn |
| Mar 31, 2024 | 510.33 Mn |
| Dec 31, 2023 | 547.66 Mn |
| Sep 30, 2023 | 583.14 Mn |
| Jun 30, 2023 | 625.24 Mn |
| Mar 31, 2023 | 662.57 Mn |
| Dec 31, 2022 | 557.32 Mn |
| Sep 30, 2022 | 447.76 Mn |
| Jun 30, 2022 | 460.31 Mn |
| Mar 31, 2022 | 473.24 Mn |
| Dec 31, 2021 | 494.37 Mn |
| Sep 30, 2021 | 513.59 Mn |